Autopsy and Photon Counting Computed Tomography to Evaluate Thromboses Related to Central Venous Catheters
Launched by THOMAS KANDER · May 11, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how often blood clots, known as thromboses, occur in patients with central venous catheters (CVCs), which are tubes placed in large veins to help with medical treatment. The study is split into two parts. In the first part, researchers will look at deceased patients who had CVCs and are undergoing autopsy. Before the autopsy, these patients will undergo a special type of CT scan to see if there are any hidden blood clots. In the second part, living patients with CVCs, who are scheduled for CT scans without contrast dye, will also receive the same type of scan to check for these blood clots.
To participate in the study, deceased patients must have had a CVC in place and require an autopsy, with consent given by their next of kin. For living patients, they need to have a CVC and be referred for a CT scan, with their own consent. The goal is to better understand how common these hidden blood clots are, which can help improve care for patients with CVCs in the future. If you or a loved one are eligible, you can expect to undergo a non-invasive CT scan that will help researchers gather important information.
Gender
ALL
Eligibility criteria
- • Substudy 1
- Inclusion Criteria:
- • Diseased patients with an indwelling central venous catheter and a clinical indication for autopsy
- • Informed and signed consent from next of kind
- Exclusion Criteria:
- • None
- • Substudy 2 Inclusion Criteria
- • Living patients with an indwelling central venous catheter who are referred to a CT scan without iv contrast
- • Informed and signed consent from the patient
- • Exclusion Criteria
- • - GFR \<15 mL/min/1.73 m2
Trial Officials
Thomas Kander
Principal Investigator
Lund University
About Thomas Kander
Thomas Kander is an esteemed clinical trial sponsor dedicated to advancing medical research and innovation. With a strong focus on ethical practices and patient safety, Thomas Kander leads multi-phase clinical trials aimed at developing groundbreaking therapies across various therapeutic areas. The organization collaborates with leading research institutions and healthcare professionals to ensure rigorous study design, comprehensive data analysis, and adherence to regulatory standards. Committed to improving patient outcomes, Thomas Kander strives to contribute significantly to the evolving landscape of healthcare through its commitment to scientific excellence and collaboration.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, Skåne, Sweden
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0